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Abstract
Hepatitis B virus (HBV) and hepatitis delta virus (HDV) are major sources of acute and chronic hepatitis. HDV requires the
envelope proteins of HBV for the processes of assembly and infection of new cells. Both viruses are able to infect
hepatocytes though previous studies have failed to determine the mechanism of entry into such cells. This study began
with evidence that suramin, a symmetrical hexasulfated napthylurea, could block HDV entry into primary human
hepatocytes (PHH) and was then extrapolated to incorporate findings of others that suramin is one of many compounds
that can block activation of purinergic receptors. Thus other inhibitors, pyridoxal-phosphate-6-azophenyl-29,49-disulfonate
(PPADS) and brilliant blue G (BBG), both structurally unrelated to suramin, were tested and found to inhibit HDV and HBV
infections of PHH. BBG, unlike suramin and PPADS, is known to be more specific for just one purinergic receptor, P2X7.
These studies provide the first evidence that purinergic receptor functionality is necessary for virus entry. Furthermore, since
P2X7 activation is known to be a major component of inflammatory responses, it is proposed that HDV and HBV attachment
to susceptible cells, might also contribute to inflammation in the liver, that is, hepatitis.
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Introduction
Hepatitis B virus (HBV) and hepatitis delta virus (HDV) are
significant causes of chronic liver disease which often progresses to
cirrhosis, fibrosis and hepatocellular carcinoma [1,2]. HBV and
HDV are enveloped viruses. HBV encodes three related envelope
proteins and HDV, that is a subviral satellite of HBV, uses the
same proteins for virus assembly and for the infection of
susceptible cells. Contributing to the discovery of HDV was that
it makes HBV infections more damaging [3].
HBV and HDV infections target hepatocytes in the liver.
Experimentally, primary cultures of hepatocytes can be infected by
both viruses and it is considered that both may use the same or
similar mechanisms to achieve entry [4]. Studies over many years
have reported a variety of candidate host receptors for the
infection but none have been confirmed or established [4].
In 1988 we reported that suramin, a symmetrical hexasulfated
napthylurea, was able to block the infection of primary woodchuck
hepatocytes by HDV [5]. Moreover, it blocked infection of
primary duck hepatocytes by duck hepatitis B virus, a relative of
HBV. More recently, others have shown that suramin can block
infection by HBV [6]. Suramin has been demonstrated to block
infections by other animal viruses [7,8,9]. It blocks infection of
liver cells by Plasmodium falciparum sporozoites, and has been used
clinically to treat trypanosomiasis and filariasis [10,11].
Seemingly independent of these effects of suramin on infections,
others have discovered that it is an antagonist of purinergic
receptors [12]. Numerous such receptors have been characterized
and studied largely for their roles in neuronal signaling although
other studies have detected their presence on many cell types, such
as monocytes and muscle cells [13]. There are seven P2X
receptors, all of which are ligand-gated cationic receptors, which
in nature respond to extracellular ATP. They are sequence-related
and structurally have two trans-membrane domains and an
extracellular loop containing essential cysteine cross-links and five
N-linked glycosylation sites [14]. P2X7 differs from the others in
that it contains a significant (220 amino acid) C-terminal cytosolic
extension that interacts with at least 11 identified host proteins
[15] and is responsible, upon activation, for the transmission of
many membrane trafficking responses [16]. Chronic activation of
P2X7 can produce apoptosis and thus not surprisingly, expression
and activation of this receptor is tightly regulated.
Activation of some purinergic receptors by ATP or non-natural
agents such as BzATP can be blocked by suramin. Other blockers
include pyridoxal-phosphate-6-azophenyl-29,4 9-disulfonate (PPADS)
[17] and brilliant blue G (BBG) [18]. BBG is more specific for just
P2X7 [19,20,21], and because of the awareness of the importance of
P2X7 in processes such as cytokine release, inflammatory and
neuropathic pain and renal fibrosis[21], there has been a major effort
to develop more specific and potent inhibitors [19], such as
AZ11645373 [22]. As documented here we tested compounds in
addition to suramin for their effect on HDV and HBV infection of
primary human hepatocyte (PHH) cultures. PPADS and BBG were
inhibitory, leading us to assert that the functionality of one or more
purinergic receptors is essential for virus entry. And given the
reported specificity of BBG [19,20], we would suggest that activation
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susceptible cells. This novel finding has many implications for
understanding host cell entry by these and perhaps other infectious
agents.
Results
These studies were begun with HDV rather than HBV for two
reasons. First, HDV reaches maximal replication in PHH by 6
days, compared to 12 for HBV; based on our observations of the
limited viability of the primary human hepatocytes cultures, HDV
was therefore preferable. Second, for HDV we assay for
antigenomic RNA (the exact complement of the genomic RNA,
which is not present in virus, and only appears in cells as a result of
the infection process) and this has a far greater sensitivity to noise
ratio than assays for HBV.
As mentioned in the Introduction it was known that HDV
infection of primary woodchuck hepatocytes could be blocked by
suramin at 70 mM [5]. Therefore one initial aim was to determine
whether this inhibition applied to the more relevant infection of
PHH, and to compare suramin action with a synthetic preS1
peptide at 50 nM. This peptide was shown by Urban and
colleagues to act as a potent inhibitor of HDV infection [4], a
finding we have confirmed [23]. Thus, a second aim was to
compare the effects of suramin and preS1 peptide when added at
different times relative to a 3-hour exposure of PHH to HDV. A
third aim was to test in parallel heparin, which has been reported
to block infection by HBV [6,24].
As summarized in Table 1, all three compounds were found to
inhibit HDV infection when present from 21t o+16 h relative to
the 3-hour virus exposure. When present only before and during
the virus exposure the inhibition was significantly less. And yet,
when present immediately after the virus exposure, there was still
significant inhibition. Addition of the compounds at 16 h after
virus exposure had very little effect, which argues against toxicity.
Thus that observation that the inhibitors had a potent effect when
added immediately after virus exposure indicates that entry was
slow with less than 50% of the virus that attached within 3 h, as
having been able to achieve entry in that time. Further it raises the
question as to how preS1 peptide and suramin, and to a lesser
extent heparin, were able to act at a step needed after attachment,
that is, at virus entry.
As described in the Introduction another activity of suramin is
as an inhibitor of purinergic receptors [12,13]. Thus we tested the
inhibitory ability of suramin relative to two other antagonists:
PPADS and BBG. In these tests the HDV was again present for
3 h and the inhibitors, at a series of concentrations, were present
from 21t o+3 h. In all cases, to eliminate consideration of virus
that attached but only entered after the 3-hour exposure period,
preS1 peptide was added from +3t o+16 h, and infection was
assayed at 6 days.
As summarized in Fig. 1 suramin, PPADS and BBG, each gave
significant inhibition of HDV infection. To exclude the post-entry
effect of cell toxicity two controls were used. First, just as shown in
Table 1, when the inhibitors were added 16 h after virus exposure,
no significant inhibition was detected. Thus even a 24-hour
exposure administered after virus entry, did not interfere with virus
replication. Second, infections were performed with another virus,
namely with a vesicular stomatitis virus, VSV that expressed GFP.
This virus is reported to be rapidly internalized by clathrin-
mediated dynamin-2-independent endocytosis [25]. Cells were
exposed to both VSV and compound for 16 h, at which time
infection was monitored by fluorescence microscopy. At the highest
concentrations of these three compounds there was no detectable
effect on the extent of VSV infection and replication (data not
shown). Together, these two control studies support the interpre-
tation that suramin, PPADS and BBG block HDV infection via an
inhibition of an essential purinergic receptor function.
As mentioned in the Introduction there are reports that BBG,
unlike suramin and PPADS, is more specific for a single purinergic
receptor, P2X7. This particular receptor is unique relative to the
others and has many interesting roles, especially relating to
inflammation and signaling of pain. Recently this has led many to
search for inhibitors that are even more specific and more potent
[19]. AZ11645373 has been characterized as a potent non-
competitive, slowly reversible, and highly specific antagonist of
human P2X7 [22,26]. At 10 mM this compound reduced HDV
infection of PHH to 1567% (data not shown). However, this
treatment led to demonstrable cell toxicity in PHH. Also it totally
blocked the ability of VSV to infect PHH. We favor the
interpretation that this inhibitor was too inhibitory and/or specific
Table 1. Inhibition of HDV infection by preS1 peptide,
heparin, and suramin.
Time when
inhibitor
present
(hours) % HDV replication in presence of inhibitor
PreS1 peptide Heparin Suramin
21t o+16 3.161.2 9651 . 4 60.7
21t o+36 5 619 24610 967
+3t o+16 12644 3 611 2168
+16 to +40 82633 72614 75616
PHH in HGM were exposed to HDV for 3 h. PreS1 peptide (50 nM), heparin
(100 mg/ml) or suramin (70 mM) were present for the indicated periods of time.
After removal of unattached virus with two washings at +3 h, infections were
allowed to proceed out to 6 days at which time total RNA was extracted and
analyzed by qPCR for antigenomic RNA. Data are expressed relative to cells not
treated with inhibitors, along with the standard error of the mean.
doi:10.1371/journal.pone.0015784.t001
Figure 1. Inhibition of HDV infection by suramin, PPADS and
BBG. PHH were exposed to HDV in HGM for 3 h. From 21t o+3 h the
inhibitors were also present, at the concentrations indicated. At +3h
both inhibitors and virus were removed and replaced by media
containing preS1 peptide (50 nM) for the next 16 h, after which the
cells were incubated in HGM out to 6 days, at which time total RNA was
extracted and assayed by qPCR for HDV antigenomic RNA. As described
in Methods, the mean values obtained are expressed relative to
untreated control cultures. Error bars represent calculated standard
error of the mean.
doi:10.1371/journal.pone.0015784.g001
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note that many of the newer P2X7 inhibitors have been tested in
short term experiments, with exposure to cells often for periods of
only minutes, and in specifically defined media conditions. In
contrast, BBG has been tested on cultured cells and even in vivo,
with effects that are considered specific for P2X7 [27].
In the study summarized in Fig. 1 preS1 peptide was added at +3h r
to block entry of virus that had attached but failed to enter within the 3-
hour virus exposure period. In the following experiments, an
alternative strategy was used that did not require use of preS1 peptide.
A modification was to expose PHH to virus, with and without
inhibitor, for the longer period of 16 h, so as to allow a greater level of
both virus attachment and entry. A second change was to include a test
of HBV relative to HDV. Prior studies indicated that for some unclear
reasons, HBV infections of PHH were less efficient than HDV, and so
the longer infection time was advantageous.
As shown in Fig. 2A, it was found that suramin, PPADS and
BBG inhibited infection by both HDV and HBV. The extent of
infection for HDV was similar to that obtained in Fig. 1, except
that now the preS1 peptide was not used. The inhibition for HBV
was extensive but maybe not as much as for HDV.
In addition we tested the effect of oxidized ATP, oATP, a
potent antagonist of P2X7 that acts by irreversible binding to the
ATP-binding site [28]. As shown, oATP at 300 mM blocked both
HDV and HBV infections. This concentration is reported to be
specific for P2X7 [20]. However, in parallel controls it completely
blocked VSV infection of PHH. Also tested was KN62, a molecule
first developed as a specific cell-permeable inhibitor of the
autophosphorylation of Ca
++/calmodulin-dependent protein ki-
nase II. It is considered to inhibit calcium mobilization after
activation of human P2X7 receptors [19]. However, it had no
significant effect on HDV or HBV.
Others and we have reported that 4 to 5% polyethylene glycol,
PEG, present during the attachment and entry, can greatly
enhance the extent of HDV infection by at least 15-fold [29,30]
and others using HepaRG cells, routinely use 4% PEG for
enhancing infections with HBV [31]. We repeated the experi-
ments of Fig. 2A in the presence of 5% PEG during the 16 h
infection, with results as shown in Fig. 2B. Note that the suramin
and PPADS inhibited but not as much. The BBG inhibition now
needed the higher concentration of 50 mM. As a reference we
tested the preS1 peptide. Again there was inhibition but not as
much as in the absence of PEG (Table 1). Thus it would seem that
PEG allows an increase in the extent of infection but with some
loss in the efficiency of the inhibitors.
Discussion
Overall, these studies support the assertion that purinergic
receptor functionality is essential for the process of PHH infection
by HDV and HBV. Suramin, PPADS and BBG are known
antagonists of one or morepurinergic receptors [13,32,33] although
BBG is more specific for P2X7 [19,20]. While our data are not
sufficient to prove P2X7 is involved it is worth noting that P2X7 is
not only structurally different from the other six P2X receptors but
its activation has many consequences, some of which could
contribute to virus entry. Activation is associated with but not
limited to [13,16,32,34]: (i) prolonged opening of an ion channel
with influx of calcium and sodium ions, (ii) formation of pores in the
cell membrane, (iii) activation of caspases, (iv) activation of receptor
tyrosine kinases, (v) temporary reorganization of the actin
cytoskeleton, (vi) transient membrane blebbing, and (vii) fusion
between cells with activated P2X7. It is known that (v) and (vi) are
requirements for macropinocytosis [35]. At this time a total of 12
different viruses have been recognized as using a form of
macropinocytosis as a means of entry into susceptible cells [35].
Purinergic receptors are known to assemble homo- and hetero-
multimeric complexes in the plasma membrane [21]. Even if
purinergic receptor functionality is necessary for the infection,
further experiments would be needed to determine whether it is a
direct or indirect requirement. For example, a direct effect would
be if the virus binding to such a receptor complex actually causes
the activation whereas an indirect effect would be if a controlled
level of activation must be maintained for the virus entry even
though entry occurs at a quite different site.
As mentioned in the Introduction, we have yet to identify the
putative receptor for HDV and HBV. The inhibitor studies
reported here only support the interpretation that both viruses use
a similar mechanism [4]. The mechanism for HDV is shown here
to be slow. As shown in Table 1 both the preS1 peptide and
suramin can have a potent effect on virus entry even when added
after the virus has attached.
Further studies are needed to establish and clarify the role of
P2X7 in HDV and HBV entry. Exogenous expression of human
P2X7 cDNA sequences has been previously achieved in the 293T
cell line [33]. We repeated such expression in 293T, but it did not
Figure 2. Inhibition of HDV and HBV infections by inhibitors of purinergic receptors. PHH in HGM were exposed to HDV (red) or HBV
(blue) for 16 h in the absence (panel A) or presence (panel B) of 5% PEG, along with the indicated inhibitors and their concentrations. After 16 h
media was changed to HGM and the infections allowed to continue for 6 or 12 days, for HDV and HBV, respectively, at which times total RNA was
extracted and assayed by qPCR as described in Methods. Evaluation was as in Fig. 1.
doi:10.1371/journal.pone.0015784.g002
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there are associated complications. These include P2X7 expres-
sion and function vary between tissues and with species [33],
human P2X7 exists in at least 7 different spliced forms [36], and
there are many genetic polymorphisms [37]. Even more, the
majority of the protein is often present in the cytosol rather than at
the cell surface [38]. And for stability and functionality at the cell
surface there are requirements for hetero- and homo-multi-
merization [21], as well as a requirement for extensive N-linked
glycosylation [14]. Thus, appropriate expression and functionality
of P2X7 could be a major contributor to the specific targeting of
HDV and HBV to human hepatocytes.
The observation that suramin, PPADS and BBG give
inhibitions very similar to the preS1 peptide and even to heparin
needs to be explained. We previously reported that when preS1
sequences either alone or fused to the N-terminus of an
immunoglobulin heavy chain, are expressed by transfection of
cells, the proteins are efficiently secreted [23]. This shows that the
preS1 region can act as an uncleaved signal peptide, and is
consistent with observations that synthetic preS1 peptide can make
efficient interactions with hepatocyte membranes [39]. Others
have shown that suramin can block entry of a malarial parasite by
inhibiting secondary processing of the N-terminal signal sequence
of an essential surface protein [11]. Therefore, a speculation is that
post-attachment processing of preS1 domains on the surface of
HDV and HBV is essential for virus entry, and that this processing
can be inhibited by heparin and preS1 peptide as well as inhibition
of purinergic receptor functionality.
If the attachment of HDV and HBV to hepatocytes does in fact
activate P2X7, even transiently, this could be linked to the
knowledge that P2X7 is a regulator of several key inflammatory
molecules, including IL-1b, IL-18, TNF-alpha and IL-6 [40]. Thus,
the attachment of virus to hepatocytes, and maybe also to non-
hepatocytes [41], such as Kupffer cells in the liver, could contribute
to an inflammatory response, in this case, hepatitis. We have
detected in PHH by immunoblot a 60 kDa band consistent with
P2X7 expression (data not shown). Others have reported
hepatocyte P2X7 protein as detected by immunostaining and
mRNA detected by northern [41,42]. Inflammation in the liver can
also be mediated by P2X7 activation [43]. Thus our findings allow
the speculation that HBV and HDV might contribute to liver
damage, damage that might be addressed using specific P2X7
antagonists [44]. While it is not uncommon that patients with a high
load of HBV show no signs of liver inflammation [1], it is also true
that HDV titers reach levels at least 100-fold that of HBV and that
HDV coinfections are much more damaging that HBV alone [2].
Materials and Methods
Materials
Suramin was obtained at originally described [5]. Heparin,
PPADS, BBG, KN62, oATP and AZ11645373 were obtained from
Sigma.The chemicallysynthesized preS1 2–48myristoylated peptide
(genotype D, subtype ayw) was a gift from Stephan Urban [45].
Viruses
Assembly of HDV was as previously described [30]. Briefly,
Huh7 cells [46] were transfected with a plasmid to initiate HDV
genome replication and a plasmid to express the envelope proteins
of HBV (genotype A, subtype adw2). Media harvested from days
6–8, 8–10, and 10–13 was clarified by low speed centrifugation.
The virus was precipitated by 10% PEG, collected by centrifu-
gation and resuspended in serum-free media, using one hundredth
of the original volume. Aliquots were stored at 270uC. The source
of HBV was the HepAD38 system developed by Ladner et al.
[47]. These cells contain an integrated HBV sequence with
expression under TET-off control. As for HDV, the tissue culture
fluids were collected, clarified and then concentrated by PEG
precipitation. Vesicular stomatitis virus (VSV) with an added gene
for GFP, was provided by Siddarth Balachandran.
Primary human hepatocytes
Primary human hepatocytes (PHH) in a 48-well format, plated
on rat tail collagen, were obtained from Cellzdirect or Celsis, and
maintained on the recommended hepatocyte growth medium
(HGM), with supplements but not including fetal calf serum.
Infections
Infection of one well of a 48-well plate used 5 mL of concentrated
virus in 0.2 ml HGM. In practice the observed infection efficiencies
were around 0.1–0.5%, using immunostaining for delta antigen to
detect HDV infected cells at 6 d after infection. As indicated, in some
experiments 5% PEG was added during 16 h exposure of cells to
virus (and inhibitor), a strategy that increased the number of infected
cells by at least 15-fold [30]. In another strategy (Fig. 1), cell were
exposed to virus (and inhibitor) for only 3 h, after which media was
removed and cells washed and then incubated for 16 h with media
containing 50 nMof a synthetic peptide containing the N-terminusof
the preS1 region of the large HBV envelope protein. This peptide
acts as an inhibitor of further entry of virus into susceptible cells
([45,48] and unpublished observations). All infections were per-
formed in at least triplicate except for control infections where six
separate culture wells were infected. Media was changed every 2–3
days. Typically infections extended for 6 and 12 days for HDV and
HBV, respectively.
Assays of virus infection
At the end of the infection period media was removed and
immediately replaced with 0.5 ml of Tri Reagent (Molecular
Research Center). RNA was then extracted according to
manufacturer’s instructions except that 10 mg of carrier dextran
was added to facilitate the ethanol precipitation steps. Aliquots of
RNA were DNase-treated immediately prior to qPCR assays to
avoid what might be plasmid DNA surviving from the HDV
assembly. HDV assays were directed against the antigenomic
RNA of HDV, a species not detectably present in HDV particles,
using primers as described in Gudima et al. [30]. HBV assays were
designed to detect pregenomic RNA as described by Loeb et al.
[49]. The qPCR data were averaged and the standard deviation of
the mean determined. The mean percentages shown are expressed
relative to the untreated control samples as 100%, and the error
bars represent compounding errors for treated and untreated
samples. VSV infections were monitored after 16 h of exposure of
cells to an MOI 0.01 in the absence or presence of compound.
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